Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma
Enrollment: 955
Actual Study Start Date: December 13, 2013
Study Completion Date: March 1, 2017
Primary Completion Date: December 12, 2016 (Final data collection date for primary outcome measure)
Arms:
- Placebo Comparator: Placebo
- Experimental: MEDI9929 - Low Dose
- Experimental: MEDI9929 - Medium Dose
- Experimental: MEDI9929 - High Dose
Related journal: Tezepelumab in Adults with Uncontrolled Asthma.
| Category | Value |
|---|---|
| Date last updated at source | 2017-04-13 |
| Study type(s) | Interventional |
| Expected enrolment | 955 |
| Study start date | 2013-12-13 |
| Estimated primary completion date | 2016-12-12 |